In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on Vertex Pharmaceuticals (VRTX) and increased his price target to $107.00 (from $92.
In a research note released today, Maxim Group assumed coverage on Advanced Cell Technology, Inc. (ACTC) with a Buy rating and a price …
